Sun Pharma signs licensing deal for LIB bad-cholesterol drug
In short
Sun Pharma said it has made a licensing deal for LIB Therapeutics’ bad-cholesterol drug. LIB will get an upfront payment, milestone payments, and royalties on sales.
The deal could bring the drug to more markets, but the exact money involved and full territory details are not stated here.
What the reporting says
Sun Pharma said in a filing that LIB Therapeutics will receive upfront and future milestone payments plus royalties on net sales in the licensed territories. The publisher summary says the arrangement covers a bad-cholesterol treatment, but it does not state the payment amounts or the full geography in the excerpt. The commercial impact depends on approvals and sales that are not yet detailed.
Why it matters
Sun Pharma said in a filing that LIB Therapeutics will receive upfront and future milestone payments, plus royalties based on net sales in the licensed territories. The reporting identifies the agreement as a global licensing deal for a bad-cholesterol treatment, but the excerpt does not state the amounts or all territories. The key parties are Sun Pharma and LIB Therapeutics, with possible effects on future drug sales.